Department of Virology, PAHO/WHO Collaborating Center for the Study of Dengue and its Vector, Pedro Kouri Tropical Medicine Institute, Autopista Novia del Mediodía, Km 6, Apdo 601, Marianao 13, Havana, Cuba.
Expert Rev Vaccines. 2010 Feb;9(2):137-47. doi: 10.1586/erv.09.139.
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. Domain III has emerged as a promising region for a subunit vaccine candidate. Here, we review the current state of knowledge on vaccine candidates based on domain III. Due to the results obtained concerning the immune response and protection in mice and monkeys, particular attention is paid to the chimeric protein domain III fused to p64k of Neisseria meningitidis.
登革热疫苗应该能同时诱导针对四种登革热病毒的长期持久保护,同时避免病毒感染的免疫增强。登革热包膜蛋白的结构域 III 与受体结合有关,也是特定中和抗体的靶标。结构域 III 已成为亚单位疫苗候选物的一个有希望的区域。在此,我们综述了基于结构域 III 的疫苗候选物的最新知识。由于在小鼠和猴子中获得的关于免疫反应和保护的结果,特别关注与脑膜炎奈瑟菌 p64k 融合的嵌合蛋白结构域 III。